Mind Medicine Shares Rise After Oregon Reportedly Allows Use of Substance in Hallucinogenic Mushrooms - Marketscreener.com

1 year ago 45

01/03/2023 | 04:08pm EST

MT Newswires 2023

All quality about MIND MEDICINE (MINDMED)

04:08p Mind Medicine Shares Rise After Oregon Reportedly Allows Use of Substance successful Hallucinog.. MT 2022 Certain Warrants of Mind Medicine Inc. are taxable to a Lock-Up Agreement Ending connected 26-.. CI 2022 Certain Restricted Stock Units of Mind Medicine Inc. are taxable to a Lock-Up Agreement.. CI 2022 Certain Stock Options of Mind Medicine Inc. are taxable to a Lock-Up Agreement Ending o.. CI 2022 Certain Common Shares of Mind Medicine Inc. are taxable to a Lock-Up Agreement Ending o.. CI 2022 Mind Medicine Inc.(NasdaqCM:MNMD) added to S&P TMI Index CI 2022 EF Hutton Initiates Mind Medicine astatine Buy With $21 Price Target MT 2022 MindMed to Participate successful the Canaccord Genuity New Paradigms and Treatment Approaches .. PR 2022 Mind Medicine (MindMed) Initiated astatine Outperform by RBC With $5 Price Target, Speculativ.. MT 2022 FCM MM Holdings LLC Sends a Letter to Mind Medicine Inc CI

More news

Analyst Recommendations on MIND MEDICINE (MINDMED)

2022 EF Hutton Initiates Mind Medicine astatine Buy With $21 Price Target MT 2022 Mind Medicine (MindMed) Initiated astatine Outperform by RBC With $5 Price Target, Speculativ.. MT 2022 HC Wainwright Adjusts Mind Medicine's Price Target to $75 from $5, Retains Buy Rating MT

More recommendations

Financials (USD)

Sales 2022 - - - Net income 2022 -69,0 M - - Net currency 2022 138 M - - P/E ratio 2022 -0,96x Yield 2022 -

Capitalization 83,7 M 83,7 M - EV / Sales 2022 - EV / Sales 2023 - Nbr of Employees 41 Free-Float -

More Financials

Chart MIND MEDICINE (MINDMED)

Duration : Period :

Full-screen chart

Technical investigation trends MIND MEDICINE (MINDMED)

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bearish	Bearish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell Buy
Mean consensus	BUY
Number of Analysts	8
Last Close Price	2,20 $
Average people price	27,63 $
Spread / Average Target	1 156%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Robert Barrow	Chief Executive Officer & Director
Miri Halperin Wernli	Executive President
Schond L. Greenway	Chief Financial Officer
Carol Ann Vallone	Chairman
Daniel R. Karlin	Chief Medical Officer

More astir the company

1. Homepage
2. Health
3. Mind Medicine Shares Rise After Oregon Reportedly Allows Use of Substance in Hallucinogenic Mushrooms - Marketscreener.com